News and Announcements
Imugene Limited Raised $3.0m from Options Plan
- Published April 06, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU), an immune-oncology company is pleased to announce that it has raised approximately $3.0m as part of the Company’s option plan which expired on 31st March 2017.
KEY TAKEAWAYS:
- The price for shares exercised under the option plan was 1.5 cents per share.
- The unlisted options are to be issued in recognition of the additional services he has performed which has been deemed far in excess of the usual services of a Non-Executive Director of a company with Imugene’s positioning together with additional services Dr. Axel Hoos continues to provide.
IMU’s CEO, Leslie Chong said today “we are pleased with the outcome of the options plan which further places Imugene in a solid position to continue the development of our Her-2 focused clinical candidate, HER-Vaxx, plus our broader mimotope platform and arginine modulator program.”
The Company are also delighted that three prominent existing shareholders, Private Portfolio Managers, Platinum Asset Management and Celtic Capital, have increased their investment in Imugene via their roles as underwriters to the plan,” said Ms Chong.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
